Date: 2014-12-02
Type of information: Nomination
Compound: chief medical officer, vice president
Company: Dimension Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 2, 2014, Dimension Therapeutics, a gene therapy company advancing novel treatments for hemophilia and rare diseases, announced that Eric Crombez, former senior medical director, Global Clinical Development, at Shire, has been appointed to the newly created position of chief medical officer. Dr. Crombez will lead Dimension’s team advancing the company’s development pipeline of novel gene therapy candidates into clinical testing. Dimension’s lead, wholly owned program in hemophilia B is anticipated to enter clinical testing in 2015. Dr. Crombez will report directly to Dimension’s CEO Annalisa Jenkins, MBBS, MRCP. Dr. Crombez brings to Dimension extensive experience and expertise in the development and execution of clinical development programs for rare genetic disorders. While at Shire, Dr. Crombez served as medical director and then senior medical director of Global Clinical Development. He played a key role in the advancement of the pivotal trials and global marketing registration submissions for VPRIVTM (velaglucerase alfa for injection), Shire’s enzyme replacement therapy for the treatment of Type 1 Gaucher disease which is now available in the US and more than 40 other countries. Dr. Crombez also played a key role in the translation of Shire’s intrathecal enzyme replacement therapy program for Metachromatic Leukodystrophy from bench research into clinical trials. Previously, Dr. Crombez was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and has authored more than 40 peer-reviewed articles, book chapter and presentation abstracts. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit. Dr. Crombez completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine.
- In addition, Dimension announced the appointment of Stephanie Haller, Shire’s former director, Clinical Programs, Early Phase Development, to the newly created position of Vice President of Clinical Operations. The appointments of Dr. Crombez and Ms. Haller are effective immediately. Ms. Haller brings to Dimension broad experience in the design and successful management of large, global clinical trial programs. Most recently, she served as director of Clinical Programs, Device Team and Early Phase Development at Shire, responsible for the execution of global clinical development in rare genetic diseases. Previously, at Genzyme Corporation, Ms. Haller held clinical trial management roles of increasing responsibility, attaining the position of associate director, Clinical Research. Prior to this, she held clinical research positions at Muro Pharmaceuticals (part of Asta Medica) and ICON Clinical Research. Ms. Haller received her B.A. degree in psychology from Denison University and is a candidate for an M.S. degree in experimental psychology from Villanova University.
Financial terms:
Latest news:
Is general: Yes
